middle.news
Recce Pharmaceuticals Passes Indonesian Site Inspection for Phase 3 Trial
11:22am on Tuesday 21st of April, 2026 AEST
•
Healthcare
Read Story
Recce Pharmaceuticals Passes Indonesian Site Inspection for Phase 3 Trial
11:22am on Tuesday 21st of April, 2026 AEST
Key Points
Indonesian regulator completes inspection with no findings
Phase 3 patient dosing continues at five sites
Interim data expected after 155 patients enrolled
Regulatory approval targeted for calendar year 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE